• Search
  • Advanced Search

Review

June 23, 2021


Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma
Sung Won Lee, Jonggi Choi, Seung Up Kim, et al.
Clin Mol Hepatol. 2021;27(3):402-412.

Over the past several decades, entecavir (ETV) and tenofovir disoproxil fumarate (TDF) have remained the first-line antiviral agents in several international guidelines. These two antiviral agents have shown similar short...

Review

December 3, 2020


Anti-fibrotic treatments for chronic liver diseases: The present and the future
Naoshi Odagiri, Tsutomu Matsubara, Misako Sato-Matsubara, et al.
Clin Mol Hepatol. 2021;27(3):413-424.

Liver fibrosis reflects tissue scarring in the liver due to the accumulation of excessive extracellular matrix in response to chronically persistent liver injury. Hepatocyte cell death can trigger capillarization of...

Review

December 3, 2020


β-blockers in advanced cirrhosis: More friend than enemy
Ki Tae Yoon, Hongqun Liu, Samuel S. Lee
Clin Mol Hepatol. 2021;27(3):425-436.

Nonselective beta-adrenergic blocker (NSBB) therapy for the prevention of initial and recurrent gastrointestinal bleeding in cirrhotic patients with gastroesophageal varices has been used for the past four decades. NSBB therapy...

Review

January 28, 2021


Changes in the epidemiology and management of bacterial infections in cirrhosis
Salvatore Piano, Marta Tonon, Paolo Angeli
Clin Mol Hepatol. 2021;27(3):437-445.

Patients with cirrhosis are susceptible to develop infections because of immune dysfunction, changes in microbiome and increase in bacterial translocation from the gut to systemic circulation. Bacterial infections can worse...

Original Article

February 2, 2021


Outcomes after liver transplantation in Korea: Incidence and risk factors from Korean transplantation registry
Jong Man Kim, Deok Gie Kim, Jihyun Kim, et al.
Clin Mol Hepatol. 2021;27(3):451-462.

Background/Aims: To analyze the incidence and risk factors of outcomes after liver transplantation (LT) in the Korean population. Methods: This study analyzed data from the liver cohort of Korean Organ Transplantation...

Original Article

February 15, 2021


Serum milk fat globule-EGF factor 8 protein as a potential biomarker for metabolic syndrome
Han Ah Lee, Jihwan Lim, Hyung Joon Joo, et al.
Clin Mol Hepatol. 2021;27(3):463-473.

Background/Aims: Useful biomarkers for metabolic syndrome have been insufficient. We investigated the performance of serum milk fat globule-EGF factor-8 (MFG-E8), the key mediator of inflammatory pathway, in diagnosis of metabolic...

Original Article

February 19, 2021


The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-infected patients
Yu Jun Wong, Prem Harichander Thurairajah, Rahul Kumar, et al.
Clin Mol Hepatol. 2021;27(3):474-485.

Background/Aims: Despite the disproportionally high prevalence rates of hepatitis C virus (HCV) amongst the incarcerated population, eradication remains challenging due to logistic and financial barriers. Although treatment prioritization based on...

Original Article

February 23, 2021


Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort
Yi-Wen Ting, Amanda Shen-Yee Kong, Shamsul Mohd Zain, et al.
Clin Mol Hepatol. 2021;27(3):486-498.

Background/Aims: 17β-hydroxysteroid dehydrogenase 13 (HSD17B13) variants were recently reported to have significantly lower odds of non-alcoholic fatty liver disease (NAFLD). This is a two-part study that aimed to evaluate the...

Original Article

February 26, 2021


Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B
Lilian Yan Liang, Hye Won Lee, Vincent Wai-Sun Wong, et al.
Clin Mol Hepatol. 2021;27(3):499-509.

Background/Aims: Serum fibrosis scores comprised of common laboratory tests have high utility to assess severity of liver fibrosis. We aimed to derive and validate a hepatocellular carcinoma (HCC) risk score...
Current Issue
Volume 27(3); Jul 2021

"Most viewed" articles are from the articles published during the last six months

Review
1578
Anti-fibrotic treatments for chronic liver diseases: The present and the future
Naoshi Odagiri, Tsutomu Matsubara, Misako Sato-Matsubara, Hideki Fujii, Masaru Enomoto, Norifumi Kawada
Clin Mol Hepatol. 2021;27(3):413-424.   Published online December 3, 2020
Special topic: Alcoholic liver diseases
The 14th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPDC)
Programmed cell death in alcohol-associated liver disease
Tatsunori Miyata, Laura E. Nagy
Clin Mol Hepatol. 2020;26(4):618-625.   Published online September 21, 2020
Guideline
1619
KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Seong Hee Kang, Hye Won Lee, Jeong-Ju Yoo, Yuri Cho, Seung Up Kim, Tae Hee Lee, Byoung Kuk Jang, Sang Gyune Kim, Sang Bong Ahn, Haeryoung Kim, Dae Won Jun, Joon-Il Choi, Do Seon Song, Won Kim, Soung Won Jeong, Moon Young Kim, Hong Koh, Sujin Jeong, Jin-Woo Lee, Yong Kyun Cho
Clin Mol Hepatol. 2021;27(3):363-401.   Published online June 22, 2021
Review
1428
Pathologic differential diagnosis of metastatic carcinoma in the liver
Jeong Hwan Park, Jung Ho Kim
Clin Mol Hepatol. 2019;25(1):12-20.   Published online October 5, 2018
Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop
Hyung Joon Yim, Ji Hoon Kim, Jun Yong Park, Eileen L. Yoon, Hana Park, Jung Hyun Kwon, Dong Hyun Sinn, Sae Hwan Lee, Jeong-Hoon Lee, Hyun Woong Lee
Clin Mol Hepatol. 2020;26(4):411-429.   Published online August 28, 2020
1470
KASL clinical practice guidelines for management of chronic hepatitis B
Clin Mol Hepatol. 2019;25(2):93-159.   Published online June 12, 2019
Original Article
The dilemma of differentiating between acute hepatitis B and chronic hepatitis B with acute exacerbation: Is quantitative serology the answer?
Sujata Lall, Pragya Agarwala, Guresh Kumar, Manoj Kumar Sharma, Ekta Gupta
Clin Mol Hepatol. 2020;26(2):187-195.   Published online April 7, 2020
Review
1580
Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects
Takuji Torimura, Hideki Iwamoto
Clin Mol Hepatol. 2021;27(2):236-245.   Published online December 3, 2020
1585
Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease
Karn Wijarnpreecha, Elizabeth S. Aby, Aijaz Ahmed, Donghee Kim
Clin Mol Hepatol. 2021;27(2):221-235.   Published online December 3, 2020
1448
Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update
Tae-Hyung Kim, So Yeon Kim, An Tang, Jeong Min Lee
Clin Mol Hepatol. 2019;25(3):245-263.   Published online February 14, 2019
1612
From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
Seong Hee Kang, Yuri Cho, Soung Won Jeong, Seung Up Kim, Jin-Woo Lee
Clin Mol Hepatol. 2021;27(2):257-269.   Published online March 22, 2021
Guideline
1494
KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications
Clin Mol Hepatol. 2020;26(2):83-127.   Published online January 10, 2020
Original Article
1570
Significant down-regulation of growth hormone receptor expression revealed as a new unfavorable prognostic factor in hepatitis C virus-related hepatocellular carcinoma
Ching-Chih Lin, Ta-Wei Liu, Ming-Lun Yeh, Yi-Shan Tsai, Pei-Chien Tsai, Chung-Feng Huang, Jee-Fu Huang, Wan-Long Chuang, Chia-Yen Dai, Ming-Lung Yu
Clin Mol Hepatol. 2021;27(2):313-328.   Published online December 14, 2020
Special topic: Alcoholic liver diseases
The 14th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPDC)
The effect of moderate alcohol drinking in nonalcoholic fatty liver disease
Jong Hwa Choi, Won Sohn, Yong Kyun Cho
Clin Mol Hepatol. 2020;26(4):662-669.   Published online September 25, 2020
The lymphatic system in alcohol-associated liver disease
Reiichiro Kondo, Yasuko Iwakiri
Clin Mol Hepatol. 2020;26(4):633-638.   Published online September 21, 2020
Review
1514
Novel biomarkers for the management of chronic hepatitis B
Takako Inoue, Yasuhito Tanaka
Clin Mol Hepatol. 2020;26(3):261-279.   Published online June 15, 2020
1579
The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future
Yusuke Watanabe, Atsunori Tsuchiya, Shuji Terai
Clin Mol Hepatol. 2021;27(1):70-80.   Published online December 3, 2020
Immunologic strategies and outcomes in ABO-incompatible living donor liver transplantation
Jongwook Oh, Jong Man Kim
Clin Mol Hepatol. 2020;26(1):1-6.   Published online March 26, 2019
1472
The fibrogenic process and the unleashing of acute-on-chronic liver failure
Guillermo Nahúm López-Sánchez, Mayra Dóminguez-Pérez, Misael Uribe, Natalia Nuño-Lámbarri
Clin Mol Hepatol. 2020;26(1):7-15.   Published online June 14, 2019
Original Article
1581
Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B
Mi Young Jeon, Beom Kyung Kim, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim
Clin Mol Hepatol. 2021;27(2):295-304.   Published online December 3, 2020
Review
1583
Current and future strategies for the treatment of chronic hepatitis C
Omar Alshuwaykh, Paul Y. Kwo
Clin Mol Hepatol. 2021;27(2):246-256.   Published online December 3, 2020
1621
Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma
Sung Won Lee, Jonggi Choi, Seung Up Kim, Young-Suk Lim
Clin Mol Hepatol. 2021;27(3):402-412.   Published online June 23, 2021
1459
Sarcopenia: Ammonia metabolism and hepatic encephalopathy
Ankur Jindal, Rakesh Kumar Jagdish
Clin Mol Hepatol. 2019;25(3):270-279.   Published online April 22, 2019
Original Article
Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging
Sunyoung Lee, Seung-seob Kim, Dong ryul Chang, Hyerim Kim, Myeong-Jin Kim
Clin Mol Hepatol. 2020;26(3):340-351.   Published online June 4, 2020
1598
Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial
Do Seon Song, Won Kim, Sang Hoon Ahn, Hyung Joon Yim, Jae Young Jang, Young Oh Kweon, Yong Kyun Cho, Yoon Jun Kim, Gun Young Hong, Dong Joon Kim, Young Kul Jung, Joo Hyun Sohn, Jin-Woo Lee, Sung Jae Park, Byung Seok Lee, Ju Hyun Kim, Hong Soo Kim, Seung Kew Yoon, Moon Young Kim, Kwan Sik Lee, Young Suk Lim, Wan Sik Lee, Jin Mo Yang, Kyun-Hwan Kim, Kwang-Hyub Han, Soon Ho Um
Clin Mol Hepatol. 2021;27(2):346-359.   Published online January 25, 2021
Review
1569
Recent updates on the management of autoimmune hepatitis
Atsumasa Komori
Clin Mol Hepatol. 2021;27(1):58-69.   Published online December 10, 2020
1547
Managing liver cirrhotic complications: Overview of esophageal and gastric varices
Cosmas Rinaldi Adithya Lesmana, Monica Raharjo, Rino A. Gani
Clin Mol Hepatol. 2020;26(4):444-460.   Published online October 1, 2020
Original Article
1589
Direct comparison of biopsy techniques for hepatic malignancies
Shang-Chin Huang, Ja-Der Liang, Shih-Jer Hsu, Tzu-Chan Hong, Hung-Chih Yang, Jia-Horng Kao
Clin Mol Hepatol. 2021;27(2):305-312.   Published online December 3, 2020
Review
1495
Switching to systemic therapy after locoregional treatment failure: Definition and best timing
Sadahisa Ogasawara, Yoshihiko Ooka, Keisuke Koroki, Susumu Maruta, Hiroaki Kanzaki, Kengo Kanayama, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Tomoko Saito, Takayuki Kondo, Eiichiro Suzuki, Shingo Nakamoto, Akinobu Tawada, Tetsuhiro Chiba, Makoto Arai, Jun Kato, Naoya Kato
Clin Mol Hepatol. 2020;26(2):155-162.   Published online January 15, 2020
1568
The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease
Erica Jennison, Christopher D. Byrne
Clin Mol Hepatol. 2021;27(1):22-43.   Published online December 10, 2020

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

ABOUT
BROWSE ARTICLES
CURRENT ISSUE
FOR CONTRIBUTORS
Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: kasl@kams.or.kr
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 232
TOTAL : 575727
Close layer